Klivira
Request demo

Optimizing Aetna Ultomiris Prior Authorization Workflows

Efficiently managing Aetna Ultomiris prior authorization is critical for patient access and revenue cycle integrity, given this drug's high-volume PA requirements across Aetna's commercial and government lines.

Prior authorization for high-cost specialty medications like Ultomiris often presents significant administrative burdens, impacting patient care timelines and increasing operational costs. Understanding Aetna's specific submission channels, policy requirements, and processing nuances is essential for minimizing denials and accelerating approvals. Klivira provides the automation layer to navigate these complexities.

Aetna Ultomiris Prior Authorization Submission Channels

For medical benefit Ultomiris prior authorization requests, Aetna primarily routes submissions through the Availity provider portal for commercial and Medicare Advantage plans. X12 278 transactions are also supported via clearinghouses for impacted procedure categories. If Ultomiris falls under the pharmacy benefit, submissions are administered through CVS Caremark, Aetna's PBM, utilizing ePA partners like CoverMyMeds or Surescripts for retail scenarios, or CVS Caremark's direct provider portal for mail-order and case-managed scenarios. Some specialty injectables and infusions managed under the medical benefit may also route through a distinct specialty-pharmacy-management workflow.

Understanding Aetna's Medical Necessity Criteria for Ultomiris

Aetna's medical necessity criteria for medications like Ultomiris are published as Clinical Policy Bulletins (CPBs) in their public CPB library. These CPBs are versioned and dated, serving as the canonical source for medical necessity logic. Criteria may be internally developed or reference external sources, which are disclosed within the CPB itself. When preparing an Aetna Ultomiris prior authorization, referencing the specific CPB number and review date is crucial for ensuring compliance with current policy.

Aetna Prior Authorization Turnaround Times for Ultomiris

Prior authorization turnaround times for Ultomiris with Aetna vary based on the line of business and state regulations. For commercial plans, state-mandated minimums apply, alongside Aetna's published service-level targets and NCQA Utilization Management accreditation standards. For Medicare Advantage and Medicaid managed care plans (Aetna Better Health), Aetna is an impacted payer under CMS-0057-F, requiring 72-hour decisions for standard PA requests and 24-hour decisions for expedited requests, with phased compliance timelines for electronic PA API conformance.

Common Denial Reasons and Appeal Pathways for Ultomiris with Aetna

Common denial reasons for specialty medications like Ultomiris with Aetna often include medical necessity not met, insufficient documentation, step therapy requirements not fulfilled, off-label use without compendium support, or benefit exclusion. Aetna returns denial reasons via X12 835/277 transactions or portal status updates, utilizing CARC and RARC vocabularies. The appeal pathway typically involves reconsideration, peer-to-peer review, and formal appeal, with expedited options available for urgent care needs. Timely-filing windows for appeals vary by line of business and state.

Klivira's Role in Streamlining Aetna Ultomiris PA

Klivira integrates directly with EMR systems and payer portals to automate the complex Aetna Ultomiris prior authorization process. Our platform helps identify specific submission channels, access relevant Clinical Policy Bulletins, and track turnaround times, reducing manual effort and improving submission accuracy. By centralizing documentation and automating status checks, Klivira minimizes administrative burden and accelerates patient access to critical therapies like Ultomiris.

Frequently asked questions

How are Aetna Ultomiris prior authorizations submitted?

For medical benefit Ultomiris, submissions typically route through the Availity provider portal or via X12 278 transactions. If Ultomiris is under the pharmacy benefit, submissions are handled by CVS Caremark, often through ePA partners like CoverMyMeds or Surescripts for retail, or CVS Caremark's direct portal for mail-order.

Where can I find Aetna's medical necessity criteria for Ultomiris?

Aetna publishes its medical necessity criteria for medications such as Ultomiris in its public Clinical Policy Bulletins (CPBs) library. You should always reference the specific CPB number and its most current review date to ensure adherence to the latest policy requirements.

What are the typical turnaround times for Aetna Ultomiris PAs?

Aetna's prior authorization decision timeframes for Ultomiris depend on the line of business and state regulations. For Medicare Advantage and Medicaid plans, CMS-0057-F mandates 72 hours for standard and 24 hours for expedited requests. Commercial plans adhere to state minimums and Aetna's published targets, often aligning with NCQA UM accreditation standards.

What are common reasons for Aetna Ultomiris PA denials?

Common reasons for Aetna Ultomiris PA denials include insufficient documentation, failure to meet medical necessity criteria, not adhering to step therapy protocols, off-label use without adequate compendium support, or the service being a benefit exclusion. Denial reasons are communicated via X12 835/277 transactions or Availity portal updates.

Does Aetna support electronic prior authorization (ePA) for Ultomiris?

Yes, Aetna supports ePA for pharmacy benefit medications via partners like CoverMyMeds and Surescripts. For medical benefit Ultomiris, ePA support is more fragmented, with X12 278 transactions available. While Aetna participates in HL7 connectathons, production conformance with Da Vinci PAS IG for medical benefit ePA requires independent verification.

Related coverage

Other ultomiris prior authorization by payer

Other ultomiris prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo